These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21830422)

  • 1. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma.
    Rehem RN; El-Shikh WM
    Hepatogastroenterology; 2011; 58(107-108):949-54. PubMed ID: 21830422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma.
    Mattera D; Capuano G; Colao A; Pivonello R; Manguso F; Puzziello A; D'Agostino L
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):699-706. PubMed ID: 14974910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma.
    Ranke MB; Maier KP; Schweizer R; Stadler B; Schleicher S; Elmlinger MW; Flehmig B
    Horm Res; 2003; 60(4):174-80. PubMed ID: 14530605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?
    Morace C; Cucunato M; Bellerone R; De Caro G; Crinò S; Fortiguerra A; Spadaro F; Zirilli A; Alibrandi A; Consolo P; Luigiano C; Resta ML; Ferraù O; Spadaro A
    Eur J Intern Med; 2012 Sep; 23(6):e157-61. PubMed ID: 22863442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
    Mazziotti G; Sorvillo F; Morisco F; Carbone A; Rotondi M; Stornaiuolo G; Precone DF; Cioffi M; Gaeta GB; Caporaso N; Carella C
    Cancer; 2002 Dec; 95(12):2539-45. PubMed ID: 12467068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia.
    Wu JC; Daughaday WH; Lee SD; Hsiao TS; Chou CK; Lin HD; Tsai YT; Chiang BN
    J Lab Clin Med; 1988 Nov; 112(5):589-94. PubMed ID: 2460570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis.
    Colakoğlu O; Taşkiran B; Colakoğlu G; Kizildağ S; Ari Ozcan F; Unsal B
    Turk J Gastroenterol; 2007 Dec; 18(4):245-9. PubMed ID: 18080921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.
    Elsammak MY; Amin GM; Khalil GM; Ragab WS; Abaza MM
    Clin Biochem; 2006 Jun; 39(6):623-9. PubMed ID: 16624274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm.
    Buzzelli G; Dattolo P; Pinzani M; Brocchi A; Romano S; Gentilini P
    Am J Gastroenterol; 1993 Oct; 88(10):1744-8. PubMed ID: 8213718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
    Huynh H; Chow PK; Ooi LL; Soo KC
    Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis.
    Kuwahara T; Sakai T; Majima Y; Hirai K; Tanikawa K
    Hepatogastroenterology; 1993 Aug; 40(4):347-51. PubMed ID: 7691701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis.
    Kratzsch J; Blum WF; Schenker E; Keller E
    Exp Clin Endocrinol Diabetes; 1995; 103(5):285-91. PubMed ID: 8536056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of liver diseases using serum biomarkers.
    Cujic D; Golubovic S; Bojic-Trbojevic Z; Ilic N; Baricevic I; Nedic O
    J BUON; 2010; 15(1):141-6. PubMed ID: 20414942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum AFP and AFP-L3 in clinically distinguished hepatocellular carcinoma from patients with liver masses.
    Subwongcharoen S; Leelawat K; Treepongkaruna SA; Narong S
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S46-51. PubMed ID: 21717878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Focus on a new assay of fucosylated alpha-fetoprotein and evaluation in the biological diagnosis of hepatocellular carcinoma in cirrhosis].
    Denis I; Beaudonnet A; Pichot J; Roubille M; Gelineau M
    Ann Biol Clin (Paris); 2000; 58(1):85-90. PubMed ID: 10673618
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of insulin-like growth factor-I and insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats.
    Novosyadlyy R; Dargel R; Scharf JG
    Growth Horm IGF Res; 2005 Oct; 15(5):313-23. PubMed ID: 16098781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.
    Renehan AG; Jones J; Potten CS; Shalet SM; O'Dwyer ST
    Br J Cancer; 2000 Nov; 83(10):1344-50. PubMed ID: 11044360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.